Novo Holdings, the holding company in the Novo Group, is responsible for the management of the assets of the Novo Nordisk Foundation, which are currently valued at more than DKK 300 billion. Novo Holdings is a private limited liability company fully owned by the Novo Nordisk Foundation.
Besides being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies within life science, as well as manages a broad portfolio of financial assets.
For more information, please visit www.novoholdings.dk
As the majority shareholder in three large Danish companies, Lundbeck, Falck and ALK-Abelló, Lundbeckfonden is one of the largest, industrial foundations in Denmark. In 2015, the market value of the foundation’s commercial activities amounted to close to DKK 50 billion including a portfolio of internally managed securities of about DKK 15 billion. In addition to this, the foundation manages a portfolio of more than 20 life science investments. Lundbeckfond Emerge is the early-stage investment unit of the foundation.
With a primary focus on brain health, Lundbeckfonden annually grants DKK 400 - 500 million to support biomedical research of the highest, international quality as part of the foundation’s vision to create better lives through new knowledge.
For more information, please visit www.lundbeckfonden.com
Sunstone Life Science Ventures is an independent European venture capital investment firm located in Copenhagen Denmark, founded in 2007 by an international team of industry experts with combined entrepreneurial, operational, and financial experience. Sunstone Life Science Ventures focuses on clinical development of prescription drugs based on novel active pharmaceutical ingredients and chemical or biological entities, that are established on a substantiated hypothesis about target-antagonist/agonist effects or a detailed understanding of a pathway, molecular interaction, or the cellular/molecular biology of a disease. Since the inception, Sunstone Life Science Ventures has invested in more than 40 companies and has completed more than 20 successful IPOs and large M&A transactions.
For more information, please visit www.sunstone.eu
HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of promising companies.
Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).
For more information, please visit www.pfmhealthsciences.com
Founded in 1996, Vivo Capital is a global investment firm focused on healthcare. Vivo has approximately $4.3 billion in assets under management, invested in over 280 public and private companies worldwide. The firm is headquartered in Palo Alto, California, with additional offices in Asia. The Vivo team consists of more than 50 multi-disciplinary professionals, including, physicians, scientists, entrepreneurs, operating executives, and industry experts.
For more information, please visit www.vivocapital.com
Thoughtful Investing to Advance Biomedical Innovation
Avoro Capital is a life sciences investment firm, supporting emerging biotechnology companies globally over the course of their lifecycle.
For more information, please visit www.avorocapital.com
Created in 2009, Kurma Partners is a European leading venture capital group specialized in Life Sciences and managing two franchises: Kurma Biofund focused on therapeutics (current active fund KBIII) and Kurma Diagnostics focused on diagnostics and ehealth (current active fund Kurma Diagnotics 2). The company has €470 million under management and develops an investment strategy supported by both the selection of the best investment opportunities in Europe and the development of a "proprietary" portfolio of companies in which Kurma steps in at creation stage.
For more information, please visit www.kurmapartners.com
RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital Management to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization.
At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics.
For more information, please visit www.racap.com
Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, MD, PhD, our team of scientists, investors, and entrepreneurs takes a long-term view to value creation across all stages of public and private life science companies. We believe in a collaborative, hands-on approach, working closely with entrepreneurs to harness exciting scientific advances and build leading companies.
For more information, please visit www.samsaracap.com
Founded in 2004, PFM Health Sciences is an investment manager focused on partnering with companies that are advancing innovations that will have a measurable and sustainable impact on health outcomes. PFM leverages its experience in public market investing across the Healthcare sector to provide growth capital and strategic value to their partners.
For more information, please visit www.pfmhealthsciences.com
Soleus Capital is a healthcare investment firm primarily focused on the innovative areas of life sciences, including biotech and medtech. The Firm invests across the healthcare lifecycle from developmental-stage companies through commercial companies.
For more information, please visit www.soleuscapital.com
Idinvest Partners is a recognized player in mid-market private equity in Europe. The company has developed several complementary areas of expertise in innovation & growth capital for young and innovative European companies; in mid-market private debt; in primary and secondary investments in unlisted European companies; and in private equity advisory activities. Founded in 1997, Idinvest Partners was a subsidiary of Allianz until 2010, when the company became independent. In 2018, Idinvest Partners joined forces with Eurazeo to become a major player in Private Equity in Europe and North America with €18bn under management.
For more information, please visit www.idinvest.com
Eir Ventures is a life science focused venture fund with a strong foundation in the Nordic Biotech ecosystem. The fund invests in early stage as well as more mature opportunities. The fund seeks opportunities addressing significant unmet medical needs for new therapies, medical technology, and digital health. Eir Ventures is founded by a team of experienced life science investors and backed by a strong investor syndicate. Eir Ventures I AB is a registered alternative investment fund, under the Swedish Alternative Investment Funds Managers Act.
For more information, please visit eirventures.eu
Serrado Capital LLC is a healthcare investment firm based in New York. The firm has generated an outstanding performance track record since inception in 2010 and invests across all major subsectors of the healthcare industry.